Keltie ranked as one of Europe’s top Patent Law Firms

Press release

With offices across the UK and Ireland, Keltie is one of the leading firms of IP specialists in Europe. The firm is internationally recognised by its peers across a number of core areas.

The firm has been ranked in both the Gold and Silver bands. Keltie’s 2023 four Gold and two Silver ratings are an improvement from their 2022 ranking.

Keltie is ranked Gold for:

Electrical Engineering & Physics
IT & Software
Biotechnology, Food & Healthcare
Mechanical Engineering

And Silver for:

Chemistry & Pharmaceuticals
Materials & Nanotechnology

Alan McFarlane, CEO of Keltie commented “I am delighted to see Keltie listed again as one of the leading Intellectual Property Firms in Europe. It is always encouraging to see external recognition of the quality of our work and the value of the services we provide across all areas of IP Management. Our team of high-quality attorneys, including internationally recognised Partners, is second to none, and fully deserving of these awards”.

Europe’s Leading Patent Law Firms 2023 Listings are based on recommendations made by clients and peers to FT research partner Statista

To see the full rankings, including their methodology and details of the research process, click here.

About Keltie

Keltie is renowned for its excellence, earned by putting talented, energetic, and principled people at its heart. Headquartered in London and with offices in Cambridge, the Cotswolds, and Ireland, Keltie specialises in IP law and management. Its clients benefit from experienced IP attorneys who work across all technologies and commercial fields.

Ends

Continue reading about Keltie ranked as one of Europe’s top Patent Law Firms

Alan McFarlane

About the author More from the author

02.04.2024

Patents, plausibility and data: one year on from G 2/21

On 23 March 2023, the European Patent Office (EPO) Enlarged Board of Appeal (EBA) published its decision in case G 2/21, concerning plausibility in patent applications. The decision provided useful guidance on how much data needs to be disclosed in a patent application to overcome objections based on the grounds of lack of inventive step and insufficiency. One year on, we take a look at how the EPO has been applying this standard in the life sciences field.

01.07.2024

Q&A with Jonathan Goodacre: Leading innovations in chemistry and life sciences

To celebrate being named again as a recommended practitioner by IAM 1000, we talk to Jonathan Goodacre to discover why Cambridge is at the heart of the life sciences sector and how to solve the modern challenges of this evolving industry sector.